Boston Imaging, the U.S. headquarters of Samsung’s digital radiography and ultrasound division, has announced a supply contract between Samsung and Lunit Inc., a provider of artificial intelligence (AI)-powered solutions for cancer diagnostics. The partnership will improve the efficiency and accuracy of chest screenings, particularly in identifying critical abnormalities, by integrating Lunit’s AI technology with Samsung’s CAD AI.

“Chest X-rays are still today the most requested exam in radiography,” says Eric Sumner, head of digital radiography. “As part of our voice of customer initiatives, we are building on our prior offering of auto lung nodule detection by integrating new on-device, real-time artificial intelligence technologies.”

Sumner adds, “By partnering with Lunit, our Samsung digital radiology products will now have computer-assisted triage and notification software that analyzes adult chest X-ray images for the presence of suspected pleural effusion or pneumothorax. Patients with suspected findings will move to the top of the radiologist queue, allowing patients to be diagnosed more quickly. This will provide critical information to radiologists as they triage urgent cases.”

In the last two years, Samsung has invested significantly to improve technology for radiology leaders and administration, enhancing patient care and workflow efficiency while keeping imaging doses low.

“As advanced technologies deliver improved patient outcomes and cost savings in healthcare, our digital radiography flagship products GM85 and GC85A Vision are at the forefront of that innovation, advancing healthcare imaging with features such as “Vision Assist” and AccE Glass Free Detector,” says David Legg, head of Boston Imaging. “We are proud that the addition of Lunit’s AI-powered solutions will further radiologists’ abilities to provide efficient and comprehensive patient care.”

The Lunit AI solution software is commercially available on Samsung digital radiology products in the first quarter of 2024. As part of the collaboration with Lunit, Samsung will continue to expand on validating the AI solution to detect the 10 most common abnormalities in chest X-ray including nodule, pneumothorax, atelectasis, cardiomegaly, calcification, consolidation, pleural effusion, pneumoperitoneum, mediastinal widening, fibrosis, and support tuberculosis screening.

Samsung will offer the upgraded systems to North America and European markets and to the Middle East, South America, and Southeast Asia.